Please ensure Javascript is enabled for purposes of website accessibility
Contact us

Browse by products

Featured content

  • InVivo Plus
    abinScience’s InVivo Plus™ antibodies target CD3, PD-1, CD4, CD8, Ly6G and more, providing low-endotoxin, in vivo-grade solutions for animal model research.
    Learn more
  • Bacteria & Viruses related products
    abinScience provides high-quality tools for studying viruses, superbugs, and parasites, including monkeypox, Ebola, and other emerging pathogens, supporting diagnostics, vaccine development, and therapeutic discovery.
    Learn more
  • Neuroscience
    abinScience provides tools for studying Alzheimer's, Parkinson's, and Huntington's disease, supporting biomarkers, diagnostics, and therapy development in neuroscience.
    Learn more
  • Therapeutic Targets
    abinScience provides tools for studying therapeutic targets, including CD3E, CTLA4, PD1, PDL1, B7-H3, CEA, CD200R1, SIRPA, and CCR8, supporting biomarkers, diagnostics, and therapy development.
    Learn more
  • DNA/RNA Research Antibodies
    abinScience offers anti-dsRNA antibodies (J2, K1, K2), widely recognized in virology, immunology, and RNA research for their exceptional specificity and sensitivity, empowering scientists to explore the RNA world
    Learn more
  • Biotoxin Antibodies
    Reliable antibodies for botulinum, ricin, tetanus, and other toxins, enabling sensitive detection and toxin research.
    Learn more
  • Autoimmune Diseases
    High-specificity antibodies and ELISA kits for key targets like TNF-α, IL-6, IFN-γ, PD-1, and CTLA-4, enabling reliable cytokine detection and immune regulation studies.
    Learn more
  • MHC Complex
    Specific antibodies for MHC I, MHC II, and related molecules, supporting antigen presentation, immune response, and disease research.
    Learn more
  • TACAs Antibodies
    Targeting tumor-associated carbohydrate antigens (Tn, STn, MUC1, CA15-3, CA72-4) to support cancer immunotherapy and biomarker research
    Learn more
  • Model Organism
    Model organisms are vital tools used by researchers around the globe. These organisms share many genes with humans, are easily maintained in the lab, and have short generation times that make it easy to study the effects of genetic manipulations.
    Learn more

    • About abinScience

    News

  • Science Discovery: The Role of Erythropoietin (EPO) in Tumor Immune Evasion
    Recent research has uncovered a critical role for erythropoietin (EPO) in tumor immune evasion. Tumor cells secrete EPO, which, through the EPOR signaling pathway, suppresses the immune function of macrophages, aiding tumors in escaping immune surveillance. Blocking the EPO/EPOR signaling enhances the efficacy of PD-1 immunotherapy, offering a novel strategy for cancer treatment.
    Learn more
  • InVivoMAb™ Plus: Precision In Vivo Antibodies for Animal Models by abinScience
    The abinScience InVivoMAb™ Plus series offers over 400 high-quality in vivo antibodies, validated for purity, specificity, and functionality, ideal for research in cancer, autoimmune diseases, and infectious diseases. This page details the activity validation experiments and ELISA tests of anti-PD-1 and anti-PD-L1 antibodies in mouse models (B16-F10 and CT26), demonstrating significant tumor suppression and antigen-binding capabilities. The product list includes a range of antibodies and isotype controls designed for immune regulation and tumor immunotherapy, supported by batch stability and traceability.
    Learn more
  • CD47: Exercise While Resting! A Potential “Exercise Mimetic Factor” for Precise Muscle Metabolism Activation
    A 2025 Cell Reports Medicine study reveals CD47-blocking antibodies mimic exercise by activating AMPK in skeletal muscle, promoting fat loss, improving glucose tolerance, and preserving muscle mass in mice. Unlike GLP-1 or SGLT2 drugs, CD47 targets muscle specifically, avoiding non-target organ side effects. This “exercise mimetic” shows promise for obesity, diabetes, and muscle degenerative diseases.
    Learn more
  • FGF21 — An Emerging Metabolic Hormone Target for Reversing Metabolic Dysfunction-Associated Steatohepatitis
    A 2025 Cell Metabolism study reveals FGF21’s role in reversing metabolic dysfunction-associated steatohepatitis (MASH) through central nervous system and hepatic mechanisms. By reducing liver triglycerides and cholesterol, FGF21 improves steatosis and fibrosis in mouse models. Long-acting FGF21 drugs like Efruxifermin show promise in phase III trials, positioning FGF21 as a key therapeutic target for metabolic liver diseases.
    Learn more
  • Ebola Sudan Strain: Key Research Developments, Vaccine Trials, and abinScience Research Reagents
    In early 2025, Uganda faced an Ebola outbreak caused by the Sudan strain, prompting global attention. In response, clinical trials targeting the Sudan strain were launched. The Ebola virus, a member of the Filoviridae family, has several key proteins like GP, NP, and VP40 critical for its replication and infectivity. Additionally, research reagents, including recombinant proteins and antibodies, are crucial for advancing Ebola research, with companies like abinScience supplying essential tools for scientists worldwide.
    Learn more
  • Unlock Precision Research with Super-Affinity ™Antibody Collection
    The Super-Affinity™ Antibody Collection by abinScience offers high-affinity SAA™ clones, validated for Western Blotting, Flow Cytometry, Immunofluorescence, and ELISA. Designed for precision and reproducibility, this collection supports life science research in immunology, oncology, and neuroscience. Explore abinScience’s cutting-edge tools to elevate your experiments with exceptional performance and reliability.
    Learn more
  • New Era for Weight Loss? Oral GLP-1 Drugs Are On the Horizon
    Eli Lilly’s oral GLP-1 agonist orforglipron shows strong results in phase 3 trials, reducing blood sugar and promoting weight loss. Unlike injectables like semaglutide, this small molecule offers oral convenience. abinScience provides high-quality GLP-1-related research tools to support future innovation.
    Learn more
  • OX40: From Setbacks in Cancer Immunotherapy to a New Hope in Autoimmune Diseases
    Discover the role of OX40 in immunotherapy, focusing on OX40 antibodies for cancer research and autoimmune diseases. Learn about the latest advancements in OX40 agonists and inhibitors, including clinical trials and abinScience’s high-quality OX40-related products for researchers.
    Learn more
  • Functional Cure for Hepatitis B: Mechanistic Insights, Emerging Therapeutics, and abinScience Research‑Grade Tools
    Hepatitis B Virus (HBV) impacts over 254 million people worldwide, posing a major challenge due to its species-specific nature and lack of immunocompetent preclinical models. Its persistence, driven by covalently closed circular DNA (cccDNA), complicates curative efforts. This article explores HBV’s infection mechanisms, limitations of current treatments like nucleos(t)ide analogs, and emerging strategies such as CRISPR-based gene editing, RNA interference, and viral entry inhibition. AbinScience supports HBV research by offering research-grade biologics, enabling studies into viral entry, replication, and antigen expression to advance therapeutic development for a future free of HBV.
    Learn more
  • SLC34A2 in Focus: Unraveling Phosphate Homeostasis, Cancer Links, and abinScience Research Solutions
    SLC34A2 (NaPi2b) regulates phosphate homeostasis by facilitating inorganic phosphate uptake in epithelial cells. This article examines its role in diseases like pulmonary alveolar microlithiasis (PAM), non-small cell lung cancer (NSCLC), breast cancer, and ovarian cancer, highlighting its therapeutic potential. abinScience offers recombinant proteins and antibodies to support SLC34A2 research in cancer and genetic disorders.
    Learn more
  • Unveiling Hantaan Virus: Cutting-Edge Research Tools from abinScience to Combat HFRS
    Explore the molecular biology of Hantaan virus (HTNV), a zoonotic pathogen causing Hemorrhagic Fever with Renal Syndrome (HFRS). Learn about its structure, immune evasion, and abinScience’s tools for antiviral research and diagnostics, including recombinant proteins and antibodies.
    Learn more
  • Cholera Exposed: How Vibrio cholerae Attacks—and How We Fight Back
    Explore the molecular pathogenesis of Vibrio cholerae, host immune responses, and global vaccine development. Discover 18 high-quality antibodies and recombinant proteins from abinScience designed for cholera research, diagnostics, and vaccine evaluation.
    Learn more

    • Quick access

    Contact us

    • +33(0)3 90 20 54 70

    • info@abinscience.com

    • 19 rue de la Haye 67300 Schiltigheim France

    Copyright © 2025 abinScience. All Rights Reserved. All Products are for Research Use Only